Our approach

Our solution

• Block the neurotoxic cascade by preventing the formation of oligomers in the membrane of brain cells
• Innovative specifications

To block the formation of amyloid pores in Alzheimer’s and Parkinson’s diseases, our researchers created the AmyP53 molecule, which prevents amyloid protein binding to brain cells.

The design of AmyP53 took into account multiple biochemical, biophysical and pharmacological parameters to avoid the traditional pitfalls in the development of therapeutic solutions.

• AmyP53 is the first representative of a new therapeutic class

By targeting a common mechanism directly causing symptoms, AmyP53 is the first therapeutic solution specifically designed to treat two major neurodegenerative diseases: Alzheimer & Parkinson.

The advantages of our solution

A nasal spray

AmyP53 is innovative in several ways:

  • It is the first-in-class compound of a new therapeutic class that inhibits a fundamental mechanism common to Alzheimer's and Parkinson's diseases.

  • This is a new therapeutic route that has never been exploited until now (brain gangliosides). 

  • It is not toxic in vivo: exceptional tolerance in animals well beyond the therapeutic doses envisaged in humans.

  • AmyP53 is the only drug candidate active in all forms of Alzheimer’s and Parkinson’s disease, including forms caused by genetic mutations (familial forms).

  • It will be administered by the nasal route for better comfort for patients and their families as well as caregivers.